Cargando…

Galectin-3 blockade suppresses the growth of cetuximab-resistant human oral squamous cell carcinoma

Oral squamous cell carcinoma (OSCC) is a cancer associated with high mortality (accounting for 3.1/100,000 deaths per year in Brazil in 2013) and a high frequency of amplification in the expression of the epidermal growth factor receptor (EGFR). Treatment with the EGFR inhibitor cetuximab leads to d...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yin, Peng, Cui, Shuanlong, Liao, Xiangling, Yao, Xiaoguang
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	D.A. Spandidos 2021
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8365594/ https://www.ncbi.nlm.nih.gov/pubmed/34328195 http://dx.doi.org/10.3892/mmr.2021.12325

Ejemplares similares

Adrenergic Blockade by Nebivolol to Suppress Oral Squamous Cell Carcinoma Growth via Endoplasmic Reticulum Stress and Mitochondria Dysfunction
por: Chen, Qian, et al.
Publicado: (2021)

Galectin 3 expression in primary oral squamous cell carcinomas
por: Weber, Manuel, et al.
Publicado: (2017)

Galectin-1 expression in oral squamous cell carcinoma: An immunohistochemical study
por: Salunkhe, Vaibhavi, et al.
Publicado: (2020)

Cetuximab-Induced Small Intestine Stricture in Metastatic Squamous Cell Carcinoma of the Oral Cavity
por: Eisa, Mohamed, et al.
Publicado: (2022)

Expression of Galectins 1, 3 and 9 in normal oral epithelium, oral squamous papilloma, and oral squamous cell carcinoma
por: Hossaka, Thais Ayako, et al.
Publicado: (2014)

Biomarkers of cetuximab resistance in patients with head and neck squamous cell carcinoma
por: Leblanc, Olivia, et al.
Publicado: (2020)

Expression of the chemokine CXCL14 and cetuximab-dependent tumour suppression in head and neck squamous cell carcinoma
por: Kondo, T, et al.
Publicado: (2016)

Resveratrol Targets Urokinase-Type Plasminogen Activator Receptor Expression to Overcome Cetuximab-Resistance in Oral Squamous Cell Carcinoma
por: Uzawa, Katsuhiro, et al.
Publicado: (2019)

Review of cetuximab in the treatment of squamous cell carcinoma of the head and neck
por: Merlano, Marco, et al.
Publicado: (2007)

Cost-Effectiveness of Cetuximab for Advanced Esophageal Squamous Cell Carcinoma
por: Janmaat, Vincent T., et al.
Publicado: (2016)

Cetuximab for Immunotherapy-Refractory/Ineligible Cutaneous Squamous Cell Carcinoma
por: Marin-Acevedo, Julian A., et al.
Publicado: (2023)

Eribulin sensitizes oral squamous cell carcinoma cells to cetuximab via induction of mesenchymal-to-epithelial transition
por: Kitahara, Hiroko, et al.
Publicado: (2016)

Galectin-7 as a potential predictive marker of chemo-and/or radio-therapy resistance in oral squamous cell carcinoma
por: Matsukawa, Sho, et al.
Publicado: (2014)

Complete response of recurrent oral squamous cell carcinoma treated with cetuximab in combination with radiotherapy: A case series
por: Naruse, Tomofumi, et al.
Publicado: (2022)

Galectin-8 Expression in Laryngeal Squamous Cell Carcinoma
por: Dong, Geun Woo, et al.
Publicado: (2009)

Cetuximab Rechallenge and Monotherapy in Patients with Squamous Cell Carcinoma of the Head and Neck
por: Knutzen, Greg, et al.
Publicado: (2015)

Clinical Remission of Cutaneous Squamous Cell Carcinoma of the Auricle with Cetuximab and Nivolumab
por: Chen, Alessandra, et al.
Publicado: (2018)

Tomotherapy concomitant with cetuximab, followed by cetuximab as single-agent therapy for unresectable squamous cell carcinoma of the skin: a case report
por: Falivene, Sara, et al.
Publicado: (2014)

In vitro suppression of oral squamous cell carcinoma growth by ultrasound-mediated delivery of curcumin microemulsions
por: Lin, Hung-Yin, et al.
Publicado: (2012)

Selective inhibition of PI3K110α as a novel therapeutic strategy for cetuximab-resistant oral squamous cell carcinoma
por: Tsuchihashi, Hiroki, et al.
Publicado: (2020)

Cisplatin Plus Cetuximab Inhibits Cisplatin-Resistant Human Oral Squamous Cell Carcinoma Cell Migration and Proliferation but Does Not Enhance Apoptosis
por: Choi, Hyeong Sim, et al.
Publicado: (2021)

Galectin 3 expression in regional lymph nodes and lymph node metastases of oral squamous cell carcinomas
por: Wehrhan, Falk, et al.
Publicado: (2018)

Radiotherapy Plus Cetuximab for Squamous Cell Carcinoma of the Oral Cavity: A Multicenter Retrospective Study of 79 Patients in Japan
por: Otsuru, Mitsunobu, et al.
Publicado: (2023)

Case Report: Cetuximab and nivolumab use in advanced cutaneous squamous cell carcinoma resistant to chemotherapy
por: Sernicola, Alvise, et al.
Publicado: (2019)

Clinical significance of galectin-7 in vulvar squamous cell carcinoma
por: JIANG, YING, et al.
Publicado: (2015)

Recent results of cetuximab use in the treatment of squamous cell carcinoma of the head and neck
por: Perri, Francesco, et al.
Publicado: (2009)

Efficacy of gemcitabine and cetuximab combination treatment in head and neck squamous cell carcinoma
por: MASEKI, SHINICHIRO, et al.
Publicado: (2013)

In Vivo Fluorescence Immunohistochemistry: Localization of Fluorescently Labeled Cetuximab in Squamous Cell Carcinomas
por: de Boer, Esther, et al.
Publicado: (2015)

Dramatic response of refractory metastatic squamous cell carcinoma of the skin with cetuximab/pembrolizumab
por: Hober, Candice, et al.
Publicado: (2021)

Gene expression signatures modulated by epidermal growth factor receptor activation and their relationship to cetuximab resistance in head and neck squamous cell carcinoma
por: Fertig, Elana J, et al.
Publicado: (2012)

Paclitaxel Potentiates the Anticancer Effect of Cetuximab by Enhancing Antibody-Dependent Cellular Cytotoxicity on Oral Squamous Cell Carcinoma Cells In Vitro
por: Sawatani, Yuta, et al.
Publicado: (2020)

Locally Advanced and Unresectable Cutaneous Squamous Cell Carcinoma: Outcomes of Concurrent Cetuximab and Radiotherapy
por: Samstein, Robert M., et al.
Publicado: (2014)

Recurrent squamous cell carcinoma of the skin treated successfully with single agent cetuximab therapy
por: Seber, Selcuk, et al.
Publicado: (2016)

Pneumatosis Cystoides Intestinalis after Cetuximab Chemotherapy for Squamous Cell Carcinoma of Parotid Gland
por: Petrides, Christos, et al.
Publicado: (2015)

Regulation of Heparin-Binding EGF-Like Growth Factor by miR-212 and Acquired Cetuximab-Resistance in Head and Neck Squamous Cell Carcinoma
por: Hatakeyama, Hiromitsu, et al.
Publicado: (2010)

Cetuximab-induced natural killer cell cytotoxicity in head and neck squamous cell carcinoma cell lines: investigation of the role of cetuximab sensitivity and HPV status
por: Baysal, Hasan, et al.
Publicado: (2020)

Anti-EGFR monoclonal antibody Cetuximab displays potential anti-cancer activities in feline oral squamous cell carcinoma cell lines
por: Altamura, Gennaro, et al.
Publicado: (2022)

Efficacy of concurrent chemoradiotherapy with retrograde super selective intra-arterial infusion combined with cetuximab for synchronous multifocal oral squamous cell carcinomas
por: Chen, Xuefei, et al.
Publicado: (2023)

Galectin-9 suppresses the tumor growth of colon cancer in vitro and in vivo
por: Morishita, Asahiro, et al.
Publicado: (2021)

Feasibility of Induction Docetaxel, Cisplatin, 5-Fluorouracil, Cetuximab (TPF-C) Followed by Concurrent Cetuximab Radiotherapy for Locally Advanced Head and Neck Squamous Cell Carcinoma
por: Charalambakis, Nikolaos, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_p9jqkbojfvcpbir3ia2goiqdlv